Novartis adjusts its pipeline focus, shares in the SMI spotlight
23.06.2026 - 08:08:51 | ad-hoc-news.de
By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-23, 08:05.
Novartis (CH0012005267) remains one of the most closely watched pharma names on the SIX Swiss Exchange as investors track progress on its focused late-stage pipeline. The group sits in the SMI and Stoxx Europe 50, underpinning its role in European blue-chip portfolios.
What analysts say about Novartis
On MarketScreener, 19 analysts currently cover Novartis, with 11 ratings on Buy, 7 on Hold and 1 on Sell, pointing to a broadly constructive stance on the stock. MarketScreener consensus overview The average 12-month price target sits around 112 Swiss francs, compared with a last SIX price in the low 100s, indicating modest upside potential in broker models.
UBS, JPMorgan and Goldman Sachs remain among the most influential houses in the Novartis coverage universe, with recent notes focusing on execution in immunology and oncology and the delivery of cost-efficiency measures after past restructuring steps. Reuters commentary on Novartis outlook Several analysts highlight the company’s strong free cash flow profile and its capacity to sustain dividends and selective bolt-on deals.
Key late-stage projects in focus
Novartis has concentrated its pipeline around immunology, cardiovascular, neuroscience and oncology, with about 15 phase III and registration projects currently highlighted in its investor materials. Novartis pipeline overview Among them, ligelizumab in chronic spontaneous urticaria and iptacopan in complement-mediated diseases have drawn repeated attention from sector analysts as potential multibillion-franc opportunities if data and launches are successful.
In oncology, Kisqali (ribociclib) expansion into additional breast cancer segments and the continued roll-out of Pluvicto in metastatic prostate cancer are seen as important growth pillars alongside established ophthalmology product Lucentis and cardiovascular drug Entresto. Bloomberg analysis on Novartis growth drivers The company has also been pruning lower-priority projects to keep research and development spending focused on candidates with the clearest commercial potential.
All news and analysis on the Novartis shares
Further updates on Novartis earnings, pipeline milestones and broker research can be found in the dedicated Novartis topic section and on the company’s investor relations pages.
The products behind Novartis revenue
Novartis generates a large share of its revenue from innovative medicines such as heart-failure drug Entresto, multiple sclerosis treatment Kesimpta and cancer therapies including Kisqali and Pluvicto. Novartis company overview The portfolio is complemented by ophthalmology medicines like Lucentis and Xiidra as well as established brands in immunology, neuroscience and respiratory diseases.
Where the Novartis shares trade today
The Novartis shares (CH0012005267) most recently traded on the SIX Swiss Exchange at around 100 Swiss francs, with a market capitalization near 210 billion Swiss francs as per the latest available exchange data.
Key data on the Novartis shares
- Company: Novartis AG
- ISIN: CH0012005267
- WKN: 904278
- Ticker: NOVN
- Trading venue: SIX Swiss Exchange
- Price (as of 2026-06-22, 17:30): 100.10 CHF
- Market cap: 210 billion CHF (as of 2026-06-22)
- Sector / industry: Health Care / Pharmaceuticals
- Index membership: SMI, Stoxx Europe 50, Stoxx Europe 600
- Next earnings date: not officially scheduled
This article is for informational purposes only and does not constitute investment advice or a solicitation to buy or sell any financial instrument. Figures and assessments are based on sources deemed reliable at the time of writing but cannot be guaranteed. Investors should conduct their own research and, where appropriate, consult a professional advisor.
